0000000000587772

AUTHOR

Iris Zalaudek

showing 9 related works from this author

A Brief Synopsis on Scalp Melanoma

2020

Melanoma constitutes one of the most sinister and troublesome malignancies encountered by humanity. Generally, the diagnosis of advanced melanoma connotes a grave prognosis, prompting a sense of looming threat of death, however, the early-stage detected disease responds well to robust treatment resulting in reasonable survivorship. Scalp melanomas are even more troublesome, because they typically exhibit more aggressive biologic behavior and are often diagnosed at a late stage. This review tries to comprehensively highlight the various diagnostic, therapeutic, and outcome aspects of scalp melanomas. The literature research includes peer-reviewed articles (clinical trials or scientific revie…

Melanomasmedicine.medical_specialtySkin NeoplasmsMEDLINEDermatologyEnglish languageDiseaseBreslow thickness; head and neck melanomas; melanomas; scalp melanomas; skin malignancies; Humans; Prognosis; Scalp; Head and Neck Neoplasms; Melanoma; Skin NeoplasmsBreslow thickne030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansMelanomaScalp melanomaAdvanced melanomaScalpHead and neck melanomabusiness.industryMelanomaLate stageHead and neck melanomasGeneral MedicinePrognosismedicine.diseaseDermatologyBreslow thickness; Head and neck melanomas; Melanomas; Scalp melanomas; Skin malignanciesClinical trialmedicine.anatomical_structureScalp melanomasHead and Neck NeoplasmsSkin malignancies030220 oncology & carcinogenesisScalpbusinessBreslow thickness
researchProduct

Dermoscopy of cutaneous smooth muscle neoplasms: a morphological study of 136 cases

2019

BACKGROUND: A variety of cutaneous smooth muscle neoplasms may arise in the skin and are frequently unrecognized by clinicians. There is sparse data relating to the dermoscopy of piloleiomyomas (PL), and nothing has been published about the dermoscopy of angioleiomyomas (AL) and leiomyosarcomas (LS). OBJECTIVES: To evaluate the morphological findings of a large series of cutaneous PL, AL and LS under dermoscopic observation, comparing these findings among them. METHODS: Digital dermoscopic images of 136 histopathologically confirmed cases of cutaneous smooth muscle neoplasms (114 PL, 13 AL and 9 LS) collected from 10 Hospitals in Spain, Austria and Italy were evaluated for the presence of d…

AdultLeiomyosarcomaMaleLeiomyosarcomaPathologymedicine.medical_specialtySkin NeoplasmsAngiomyomaDermoscopyDermoscopy angioleiomyoma leiomyosarcoma piloleiomyoma smooth muscle tumorsDiagnostic accuracyDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSmooth musclemedicineHumansAgedDermoscopy; angioleiomyoma; leiomyosarcoma ; piloleiomyoma; smooth muscle tumorssmooth muscle tumorsbusiness.industryLarge seriesMuscle SmoothleiomyosarcomaMiddle Agedangioleiomyomamedicine.diseaseAngiomyomaInfectious Diseases030220 oncology & carcinogenesisMuscleFemaleSmoothpiloleiomyomaAdult; Aged; Angiomyoma; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Muscle Smooth; Skin Neoplasms; DermoscopybusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

2019

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and…

AdultMalemedicine.medical_specialtyHealth Knowledge Attitudes PracticeAdolescentdisease awarenessMEDLINEDermatologyDisease.030207 dermatology & venereal diseases03 medical and health sciencesDiagnostic Self EvaluationYoung Adult0302 clinical medicineHealth caremedicineEffective treatmentHumansHidradenitis suppurativa030212 general & internal medicineMass MediaYoung adultIntensive care medicineChildAdolescent; Adult; Aged; Child; Cysts; Diagnostic Self Evaluation; Female; Health Education; Health Knowledge Attitudes Practice; Hidradenitis Suppurativa; Humans; Male; Mass Media; Middle Aged; Social Media; Young Adult; CommunicationHealth EducationAgedPracticebusiness.industryCystsInflammatory skin diseaseHealth KnowledgeCommunicationhidradenitis suppurativadisease awareness communication hidradenitis suppurativaMiddle Agedmedicine.diseaseHidradenitis SuppurativaInfectious DiseasesCystAttitudesHealth educationFemalebusinessSettore MED/35 - MALATTIE CUTANEE E VENEREESocial MediaHuman
researchProduct

Total body skin examination for skin cancer screening in patients with focused complaints

2012

Background. The value of total body skin examination (TBSE) for skin cancer screening is controversial. Objective: We sought to determine whether TBSE could be helpful in patients with focused skin symptoms who would not otherwise have undergone TBSE. Methods: In a prospective, multicenter, cross-sectional study consecutive adult patients were recruited during a period of 18 months. Physicians first inspected, problem areas and uncovered areas and then performed TBSE. Equivocal lesions detected in both steps were excised or biopsied. Primary outcomes were the absolute and relative risks of missing skin cancer and the number of patients needed to examine to detect melanoma or another maligna…

AdultMalemedicine.medical_specialtySkin NeoplasmsBiopsyprevalenceDermoscopyPhysical examinationDermatologydermatoscopyMalignancySkin Diseasesskin cancer; dermoscopy; prevention; prevalencetotal body skin examinationpreventionAdult; Aged; Biopsy; Cross-Sectional Studies; Dermoscopy; Early Detection of Cancer; Female; Humans; Male; Middle Aged; Physical Examination; Prospective Studies; Skin Diseases; Skin NeoplasmsBiopsymedicinemelanomaHumansProspective StudiesProspective cohort studyPhysical ExaminationEarly Detection of CancerAgedCross-Sectional StudieDermatoscopyintegumentary systemmedicine.diagnostic_testskin cancerbusiness.industrySkin DiseaseMelanomascreeningpigmented skin lesionsMiddle Agedmedicine.diseaseDermatologyProspective StudieCross-Sectional Studiestotal body skin examination; melanoma; skin cancer; preventionRelative riskFemalenonmelanoma skin cancerdermoscopySkin cancerbusinessHuman
researchProduct

Synthesis of the Data on COVID-19 Skin Manifestations: Underlying Mechanisms and Potential Outcomes

2021

Abstract The incidence of coronavirus disease 2019 (COVID-19)-related skin manifestations has progressively grown, in parallel with the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. The available evidence indicates that cutaneous signs are heterogeneous and can be divided as follows: a) erythematous rashes, b) lesions of vascular origin, c) vesicular rashes, d) urticarial rashes, and e) acute generalized exanthematous pustulosis (AGEP), erythema multiforme (EM) and other polymorphic/atypical reactions. Most cutaneous manifestations appear simultaneously or after respiratory and/or systemic symptoms such as fever, even if rarely urticaria has been reported as…

medicine.medical_specialtycutaneous manifestationscutaneous manifestationbusiness.industrySARS-CoV-2COVID-19DermatologyDiseaseReviewmedicine.diseaseAcute generalized exanthematous pustulosisDermatologyVirusHypersensitivity reactionImmune systemmedicineskin rashesErythema multiformeRespiratory systemChilblainsbusiness
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

2021

Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severi…

Registrie0301 basic medicineDermatitisSystemic therapy0302 clinical medicinePandemicImmunology and AllergyMedicineRegistriesatopic dermatitis; COVID; SARS‐ CoVCOVIDtreatmentatopic dermatitisatopic dermatitis; COVID; SARS-CoVSARS-CoVAtopic dermatitisDupilumabSARS‐ CoVItalyOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanatopic dermatitiAdultmedicine.medical_specialtyTeledermatologyCOVID; SARS‐CoV; atopic dermatitis treatmentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID; SARS‐CoV; atopic dermatitis; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis AtopicAtopicDermatitis Atopic03 medical and health sciencesSettore MED/35Disease severityInternal medicineatopic dermatitis treatmentHumansPandemicsPandemicbusiness.industrySARS-CoV-2SARS‐CoVCOVID-19medicine.disease030104 developmental biology030228 respiratory systemCommunicable Disease Controlatopic dermatitis; COVID; SARS-CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis Atopicatopic dermatitis COVID SARS-CoVbusiness
researchProduct

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab The…

2022

N/A

Dupilumab TherapyAntibodies Monoclonal Humanized; Disease Progression; Humans; Treatment Outcome; COVID-19; Dermatitis AtopicDermatitisAtopic dermatitis.DermatologyDupilumabAntibodies Monoclonal HumanizedAntibodiesAtopicDermatitis AtopicSettore MED/35MonoclonalImmunology and AllergyHumanshumanHumanizedAtopic dermatitistreatment outcome Antibodies Monoclonal HumanizedCOVID-19Treatment OutcomeCOVID-19 Dupilumab Therapydisease exacerbationDisease ProgressionSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanmonoclonal antibody atopic dermatiti
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct